key: cord-0983088-w29z2d1n
authors: Thachil, Jecko
title: What do monitoring platelet counts in COVID‐19 teach us?
date: 2020-05-12
journal: J Thromb Haemost
DOI: 10.1111/jth.14879
sha: 35ba1a3ba8e4000114075f092305b5111eebfb48
doc_id: 983088
cord_uid: w29z2d1n

Yang and colleagues published the relevance of thrombocytopenia in COVID-19 patients and its association with mortality in this condition in the Journal of Thrombosis and Haemostasis.1 The authors are to be applauded for the largest so-far analysis in the epidemiology of thrombocytopenia in patients with COVID-19. In addition to the association with mortality, there may be several other findings in this interesting paper which deserves mention. First of all, the study confirms that COVID-19 is not associated with significant thrombocytopenia (only 20.7% had counts less than 125 x 109/L, the lower range in this study).2,3 The 'higher' platelet counts for an illness as severe as COVID-19 is unusual and likely points towards liver activation and thrombopoietin release.

Yang and colleagues published the relevance of thrombocytopenia in COVID-19 patients and its association with mortality in this condition in the Journal of Thrombosis and Haemostasis. 1 The authors are to be applauded for the largest so-far analysis in the epidemiology of thrombocytopenia in patients with COVID-19. In addition to the association with mortality, there may be several other findings in this interesting paper that deserve mention. First of all, the study confirms that COVID-19 is not associated with significant thrombocytopenia (only 20.7% had counts < 125 × 10 9 /L, the lower range in this study). 2,3 The "higher" platelet counts for an illness as severe as COVID-19 is unusual and likely points toward liver activation and thrombopoietin release. After all, platelets can also be considered an acute phase reactant (such as ferritin, fibrinogen, C-reactive protein, which are all markedly raised in this disease) because of its antimicrobial repertoire, which is increasingly recognized by the thrombosis and hemostasis community. [4] [5] [6] The lung-specific entry of SARS-CoV-2 suggests these platelets are one of the first lines of defense and gives proof to the concept of the presence of functional megakaryocytes in the lungs. In other words, the lung megakaryocytes (a previously disputed concept) in response to the liver thrombopoietin produce a large number of platelets locally to help in the host defense. 7 In support of this, the authors do hypothesize SARS-CoV-2 could entrap megakaryocytes and block the release of platelets as another reason for thrombocytopenia, which is interesting.

But what would explain the poor prognosis from the lower platelet counts noted by Yang and colleagues?

Platelet counts < 50 × 10 9 /L are extremely rare in COVID-19.

According to the current study, the range of nadir platelet counts was 43 to 129 × 10 9 /L. Although the authors suggest bone marrow involvement by the virus as another cause for the thrombocytopenia, that the rest of the blood counts are not always significantly affected in COVID-19 (hemoglobin and white cell counts apart from lymphopenia) points away from this mechanism. A more plausible reason is platelet being consumed to form pulmonary thrombi. Thrombus formation as an anti-infective process gained momentum in the past 2 decades. 8 To serve this purpose, a bronchoalveolar hemostatic system exists to stop pathogen invasion into the bloodstream, 9 4. The timing of antiplatelet therapy -at a stage when they participate in microthrombi formation much more than the early phases when they may play a beneficial role (as described earlier) Platelets continue to surprise us by being much more than the cellular component of the hemostatic system. And studies like that of Yang and colleagues help us to understand more about these multifaceted platelets, which do far more than just forming clots.

Thrombocytopenia and its association with mortality in patients with COVID-19

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of coronavirus disease 2019 in China

Emerging roles for platelets as immune and inflammatory cells

Platelets in inflammation and immunity

Platelet secretion in inflammatory and infectious diseases

The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors

Coagulation and non-coagulation effects of thrombin

Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome